Assurance of safe, effective and timely care for patients with acute ischemic stroke can decrease stroke-related morbidity and mortality. Tenecteplase has emerged as an alternative to alteplase for thrombolytic therapy in patients with acute ischemic stroke with evidence suggesting potential improved outcomes in select patient populations. Scientific evidence, operational logistics, and cost considerations can guide institutional conversations when determining preferred formulary thrombolytic therapy.
